Bill
Bill > S3872
summary
Introduced
11/18/2024
11/18/2024
In Committee
11/18/2024
11/18/2024
Crossed Over
Passed
Dead
01/12/2026
01/12/2026
Introduced Session
2024-2025 Regular Session
Bill Summary
This bill prohibits the procurement of opioid antidotes from certain pharmaceutical manufacturers and distributors. Under the bill, the Division of Purchase and Property (division) in the Department of the Treasury, or any State agency having authority to contract for the purchase of goods or services, may only issue a request for proposal for the procurement of opioid antidotes to entities that have not been parties to any settlement with any state government over legal claims against those entities for actions that contributed to the opioid epidemic. An entity that has been a party to a settlement with any state government over a legal claim against the entity for an action that contributed to the opioid epidemic, including any of the entity's affiliates or subsidiaries, will be precluded from participating in the solicitation. Following the selection and awarding of any request for proposal for the procurement of opioid antidotes issued pursuant to this bill, the division, or any State agency having authority to contract for the purchase of goods or services, will only purchase, or use available federal funding to purchase, opioid antidotes from selected and awarded vendors that have not been parties to any settlement with any state government over legal claims against those vendors for actions that contributed to the opioid epidemic. Under the bill, any entity that has been a party to a settlement with any state government over a legal claim against the entity for an action that contributed the opioid epidemic, including any of the entity's affiliates or subsidiaries, will be precluded from selling the State opioid antidotes. However, if the entity, in a settlement entered into prior to September 1, 2024, agreed to provide the State opioid antidotes as a part of the settlement, the entity will continue to provide the State opioid antidotes until the existing settlement obligations are fulfilled
AI Summary
This bill aims to restrict the procurement of opioid antidotes (medications used to treat opioid overdoses, such as naloxone) by New Jersey state agencies from pharmaceutical manufacturers and distributors that were involved in legal settlements related to the opioid epidemic. The bill defines an "opioid antidote" as any FDA-approved drug for treating opioid overdoses, including nasal spray and other delivery methods. When the Division of Purchase and Property or any state agency seeks to purchase opioid antidotes, they may only issue requests for proposals to entities that have not been party to any state settlement over claims related to the opioid epidemic. Any pharmaceutical company that was involved in such a settlement, including its affiliates or subsidiaries, would be prohibited from participating in the procurement process or selling opioid antidotes to the state. However, if a company had previously agreed to provide opioid antidotes as part of a settlement entered into before September 1, 2024, they can continue to fulfill those existing obligations. The legislature's rationale is to ensure that the state does not purchase medications from companies that have been found to have contributed to the opioid crisis, and instead support pharmaceutical manufacturers and distributors not implicated in those legal actions.
Committee Categories
Health and Social Services
Sponsors (2)
Last Action
Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee (on 11/18/2024)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2024/S3872 |
| BillText | https://pub.njleg.gov/Bills/2024/S4000/3872_I1.HTM |
Loading...